Bruker

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) Life Science, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI Life Science segment includes enabling life science tools based on magnetic resonance technology. The BSI Nano segment offers x-ray instruments that use electromagnetic radiation with wavelengths to determine the characteristics of matter and the three-dimensional (3D) structure of molecules. The BEST segment consists of conducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research, and other applications. The company was founded by Gunther Laukien in 1960 and is headquartered in Billerica, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bruker reports robust 2022 performance, eyes growth amid challenges

Bruker's strong financial performance in 2022, driven by organic revenue growth and strategic investments, positions the company for continued success.
While facing supply chain challenges and geopolitical risks, Bruker remains optimistic about growth opportunities in proteomics and spatial biology.
Confidence in 2023 outlook is supported by strong bookings, backlog visibility, and expectations of solid organic growth in key markets.

Bruker reports strong Q1 earnings, eyes spatial biology markets

Bruker's Q1 2023 performance showcased robust revenue growth and margin improvement, with strong demand across key segments and regions.
While facing challenges like margin declines and supply chain constraints, the company is well-positioned to capitalize on opportunities in spatial biology and proteomics markets.
By focusing on innovation, capacity investments, and addressing backlog delays, Bruker aims to sustain growth momentum and meet future demand expectations.
Overall, Bruker's strategic initiatives and market positioning indicate a positive outlook for continued growth and market leadership in the analytical instruments industry.

Bruker reports strong Q2 earnings, eyes global growth opportunities

Bruker's Q2 2023 performance reflects strong revenue and EPS growth, driven by demand across key segments and regions. The company's focus on innovation and global expansion positions it well for future growth.
While facing challenges such as high lead times and supply chain issues, Bruker is proactively managing costs and investing in capacity to meet demand. Opportunities for organic growth and profitability through strategic investments and pricing trends are on the horizon.
Overall, Bruker's Q2 2023 earnings call highlights a resilient performance, strategic strengths in R&D and global presence, challenges in capacity and logistics, and opportunities for sustained growth and profitability.

Bruker reports strong Q3 earnings and eyes sustainable growth

Bruker's Q3 2023 performance reflects robust revenue and earnings growth, supported by strong organic growth and strategic acquisitions.
While facing challenges in biopharma investments and China trends, Bruker's strengths lie in its elevated backlog and growth opportunities in green tech and academic funding.
The company's focus on high-end Life Science tools in China and long-term growth prospects position it well for sustained success.
Overall, Bruker's performance in Q3 2023 showcases resilience and strategic positioning for future growth.

Bruker excels in Q4 2023, eyes accelerated growth and acquisitions

Bruker's strong Q4 2023 performance showcased robust revenue and EPS growth, though challenges like margin pressure and geopolitical risks persist. With a focus on strategic acquisitions and market opportunities, Bruker aims for continued growth and innovation.

Bruker boosts revenue guidance after Q1 growth, faces margin challenges

Bruker's Q1 2024 performance showed growth despite margin challenges, with increased revenue guidance for the year.
Strong geographic revenue growth in the Americas and Europe contrasted with a decline in Asia Pacific.
Strategic acquisitions and focus on organic growth present opportunities for Bruker in 2024.
Challenges include margin compression, dilution from integration, and lower organic growth due to order distortions.

Bruker reports robust Q2 earnings, eyes growth in key sectors

Bruker's strong Q2 performance and strategic acquisitions are driving growth in key areas like spatial biology and molecular diagnostics.
While facing margin challenges due to recent acquisitions, the company remains confident in achieving operational excellence and margin expansion.
Maintaining mid-single-digit organic revenue growth and focusing on operational efficiency position Bruker for continued success in the market.
The company's outlook remains positive with opportunities for growth through acquisitions and market demand for its innovative solutions.

Bruker reports strong Q3 earnings, eyes margin expansion in 2025

Bruker's Q3 '24 performance was strong, with revenue growth and margin improvements.
Challenges include weaker-than-expected demand in biopharma and China markets.
Anticipated opportunities lie in margin expansion and innovative solutions in 2025.
Focus on driving improvements in acquired businesses to drive growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI Nano segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Günther Laukien in 1960 and is headquartered in Billerica, MA.

TORINO, Italy--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) is pleased to announce the closing of its acquisition of ELITechGroup (“ELITech”) for €870 million in cash, excluding the carved out ELITech clinical chemistry business. ELITech is a differentiated, fast growing and profitable provider of systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology, with FY 2023 revenue of approximately EUR 150 million, and more than 80% consumables reven.

Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for its first quarter ended March 31, 2024. Bruker's President and CEO Frank H. Laukien commented: “Bruker's first quarter 2024 was well executed by our teams with continued organic revenue growth, even when compared to a very strong prior year first quarter. Demand for our innovative and differentiated products and solutions has remained solid, and we are maintaining our 5% to 7% organic reve.

Bruker Reports First Quarter 2024 Financial Results

Hologic

Illumina

Teleflex

Zimmer Biomet Hlds

Here is a sneak peek into how the five MedTech stocks, HOLX, ZBH, ILMN, TFX and BRKR, are expected to fare in their quarterly results slated to be released tomorrow.

Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?

Evaluate the expected performance of Bruker (BRKR) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Countdown to Bruker (BRKR) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS

Bruker's (BRKR) strong potential across the NANO and BioSpin segments bodes well for investors.

Here's Why You Should Buy Bruker (BRKR) Stock Right Now

Bruker (BRKR) revenues continue to be driven by the strength of end markets, including academic, government and industrial.

Bruker's (BRKR) Balanced Segmental Growth, Innovation Aid

BARCELONA, Spain--(BUSINESS WIRE)---- $BRKR #BRKR--At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying microbiology and infectious disease diagnostics and workflows in the clinical laboratory is a key goal for Bruker in support of earlier and improved patient treatment decisions. Microbial identification – towards automated.

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2024 financial results before market opening on Thursday, May 2, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2024 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide presentat.

Bruker Announces Date and Time of First Quarter 2024 Earnings Release and Webcast

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Bruker (BRKR) Q1 Earnings Expected to Decline

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that it has entered into a definitive acquisition agreement with NanoString Technologies, Inc., headquartered in Seattle, Washington, a leading provider of solutions for spatial transcriptomics and gene expression analysis. Under the asset purchase agreement, Bruker expects to acquire substantially all of the assets and rights associated with NanoString's business, including the nCounter®, GeoMx®, CosMx™ and At.

Bruker to Acquire the NanoString Business in an Asset Deal

NanoString Technologies Inc

NanoString announced Wednesday that it will be acquired by Bruker, ending the company's restructuring process that included a Chapter 11 bankruptcy plan.

Seattle biotech company NanoString to be acquired by Bruker for $392M, ending bankruptcy process

Life science tool companies have faced challenges in the post-pandemic adjustment process, but Bruker has fared better than many due to its leverage to research tools. Bruker's high exposure to potentially weaker academic and government end-markets presents challenges, but Bruker's tools address high-priority research areas in biology, pharmaceuticals, and semiconductors. Bruker is well-positioned for healthy revenue growth in 2024, with potential growth in the Chinese market and increasing interest in proteomics and spatial biology driving growth opportunities.

Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research

Bruker's (BRKR) latest novel technology facilitates the widespread application of NMR in academic basic and clinical research.

Bruker (BRKR) Introduces Magnet Technology for NMR Adoption

ASILOMAR, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT). At the 65th ENC (www.enc-conference.org), Bruker introduces the Ascend Evo 600, a novel compact 54 mm standard-bore 14.1 Tesla (6.

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

ASILOMAR, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates. At the 65th ENC (www.enc-conference.org), Bruker introduces a new ultra-fast CP/MAS iProbe as the latest innovation in solid-state.

Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (NASDAQ: BRKR) has been selected as the Instrument Business Outlook (IBO) ‘Company of the Year' for 2023. IBO cited Bruker's double-digit organic revenue growth in 2023 in all major regions, and in all business groups, demonstrating a transformed portfolio and operational strength. The IBO recognition follows Bruker's three consecutive years of double-digit organic revenue growth. The fast growth can be attributed to the Bruker innovation mo.

Bruker Selected as ‘Company of the Year' by Instrument Business Outlook

Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.

Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?

Why Is Bruker (BRKR) Up 15.7% Since Last Earnings Report?

Investors are upbeat about Bruker (BRKR) led by strong NANO group prospects and strong guidance.

Bruker (BRKR) Up 20.7% Since Last Earnings: What's Driving It?

Bruker (BRKR) advances CCS-Enabled 4D-Proteomics timsTOF solutions for immunopeptidomes and glycoproteomics at the US HUPO 2024.

Bruker (BRKR) Announces Advanced timsTOF Solutions at US HUPO

PORTLAND, Ore.--(BUSINESS WIRE)---- $BRKR #BRKR--At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows. The rapid advances in deep, at-scale proteomics, glycomics and peptidomics research solutions complement other performance-leading life-science tools for the post-genomic era by Bruker. Together they enable post-genomic molecular and cell biology research, with key insi.

Bruker Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

BASEL, Switzerland--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) is pleased to announce the successful closing of its acquisition of Chemspeed Technologies AG, a leading Swiss provider of automated laboratory R&D and QC workflow solutions. This acquisition, first announced in January 2024, marks another significant milestone in Bruker's expansion in vendor-agnostic scientific software, R&D and QC digitalization, and laboratory automation – altogether an important initiative within.

Bruker Announces Closing of Chemspeed Technologies AG Acquisition

The strength of the BSI BioSpin and CALID groups bodes well for Bruker (BRKR).

Here's Why Investors Should Retain Bruker (BRKR) Stock Now

Bruker (BRKR) announces a share purchase agreement to acquire the molecular diagnostics innovator ELITechGroup.

Bruker (BRKR) Inks Definitive Agreement to Acquire ELITechGroup

TORINO, Italy--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that it has entered into a definitive share purchase agreement with TecFin S.à r.l., a controlled affiliate of PAI Partners, a pre-eminent private equity firm, to acquire ELITechGroup, for €870 million in cash, excluding the carved out ELITech clinical chemistry business. As reported in an 8-K SEC filing on December 26, 2023, Bruker had previously entered into a put option agreement with the sellers, pending worke.

News for Bruker Stock (BRKR)